HR Execs on the Move

StrideBio

www.stridebio.com

 
StrideBio is a product-driven, fully integrated gene therapy company focused on creating and developing innovative genetic medicines with life-changing or curative potential for patients with devastating conditions, including monogenic rare disease and beyond. We leverage our proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes to overcome current limitations of first-generation gene therapies. Improved characteristics of StrideBio`s AAV vectors include evasion of pre-existing neutralizing antibodies, tissue targeting and de-targeting, enhanced potency, and manufacturability at scale. Combined with our gene construct design expertise and in-house manufacturing capabilities, StrideBio is ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.stridebio.com
  • 5 Laboratory Drive Suite 1200
    Durham, NC USA 27709
  • Phone: 984.213.7300

Executives

Name Title Contact Details

Similar Companies

Clade Therapeutics

Clade Therapeutics is a well-funded cell therapy company developing novel cell-based medicines for the treatment of cancer and other devastating diseases. The company, located in the heart of Cambridge was recently launched by an exceptional group of academic leaders and successful bioentrepreneurs converging stem cell biology, immunology, regenerative medicine, and gene editing into the next-generation of stem cell-derived medicines.

Lykan Bioscience

The combined characteristics of a modern machine (with a touch of humanity) and mythical creature symbolizes Lykan Bioscience™ as a company. The team at Lykan Bioscience operates with a highly advanced way of thinking. We offer our clients speed, agility, and control while accelerating their cell and gene therapy products from clinical through to commercial manufacturing. As part of your team, our Manufacturing Services Organization™ (MSO) will transform what is traditionally offered in the CGT industry, as we guide you through your manufacturing journey. Our mission is to partner with our clients, to maximize patient accessibility and expedite time to market for cell-based therapies.

Abattis

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market. We follow strict Standard Operating Protocols and adhere to the Law`s of Canada and Foreign Jurisdictions.    Abattis Bioceuticals Corp. aims to become a leader in the growing, testing, and distribution of medical and adult-use cannabis in North America.   Through its network of subsidiaries and partners, the company has developed an innovative GDERS (grow, dry, extract, refine, sell) strategy spanning the entire industry supply chain from seed to sale. These subsidiaries and partners specialize in cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment, and consulting services across the continent.   The company follows strict standard operating protocols and adheres to both U.S. and Canadian laws pertaining to the cultivation, testing, and sale of cannabis.

Advanced Urgent Care

Advanced Urgent Care is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Day One Biopharmaceuticals

Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine.